Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Pallavi Chiprikar & Vinayak Mastiholimath. (2023) Development of RP-HPLC based analytical method for determination of cariprazine hydrochloride in bulk drug and pharmaceutical dosage form using box-behnken statistical design. Analytical Chemistry Letters 13:3, pages 297-312.
Read now
Read now
Faiza Asghar, Bushra Shakoor, Babar Murtaza & Ian S. Butler. (2023) An insight on the different synthetic routes for the facile synthesis of O/S-donor carbamide/thiocarbamide analogs and their miscellaneous pharmacodynamic applications. Journal of Sulfur Chemistry 44:1, pages 90-147.
Read now
Read now
Rui-Xiang Yuan, Jun-Wei Xu, Lian-Hua Song, Yang-Li Qi, Hong Mou, Jian-Wei Wu, Ke-Yu Jiang & Xiao-Wen Chen. (2021) A convenient and practical synthesis of the cis isomer of the first orally active dopamine D3-Preferring D3-D2 receptor partial agonist cariprazine. Synthetic Communications 51:14, pages 2127-2134.
Read now
Read now
Felix-Martin Werner & Rafael Coveñas. (2015) New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine. Therapeutics and Clinical Risk Management 11, pages 1657-1661.
Read now
Read now
Articles from other publishers (31)
Xenia M. Hart, Moritz Spangemacher, Hiroyuki UchidaGerhard Gründer. (2023) Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antipsychotics. Therapeutic Drug Monitoring.
Crossref
Crossref
Konstantinos N. Fountoulakis, Magdalini Ioannou, Mauricio Tohen, Bartholomeus C.M. Haarman & Carlos A. ZarateJR.JR.. (2023) Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: A hypothesis based on data. European Neuropsychopharmacology 72, pages 30-39.
Crossref
Crossref
Xenia M. Hart, Christian N. Schmitz & Gerhard Gründer. (2022) Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice. Frontiers in Psychiatry 13.
Crossref
Crossref
Małgorzata Jarończyk & Jarosław Walory. (2022) Novel Molecular Targets of Antidepressants. Molecules 27:2, pages 533.
Crossref
Crossref
Adilakshmi Singavarapu, Gowri Sankar Reddipalli & Venkat Reddy Ghojala. (2022) Synthesis of Antipsychotic Drug, Cariprazine: An Improved and Commercially
Viable Synthetic Approach. Letters in Organic Chemistry 19:1, pages 64-70.
Crossref
Crossref
Javier Vilches Vázquez & Jose Manuel Gallego Rodríguez. (2022) Cariprazina como alternativa farmacológica en el tratamiento de la psicosis en la enfermedad de Parkinson. Psiquiatría Biológica 29:1, pages 100347.
Crossref
Crossref
Sameer Jauhar. 2021. Mood Disorders. Mood Disorders
236
247
.
. 2021. Mood Disorders. Mood Disorders.
Nicholas M. Barnes, Gerard P. Ahern, Carine Becamel, Joël Bockaert, Michael Camilleri, Severine Chaumont-Dubel, Sylvie Claeysen, Kathryn A. Cunningham, Kevin C. Fone, Michael Gershon, Giuseppe Di Giovanni, Nathalie M. Goodfellow, Adam L. Halberstadt, Rachel M. Hartley, Ghérici Hassaine, Katharine Herrick-Davis, Ruud Hovius, Enza Lacivita, Evelyn K. Lambe, Marcello Leopoldo, Finn Olav Levy, Sarah C. R. Lummis, Philippe Marin, Luc Maroteaux, Andrew C. McCreary, David L. Nelson, John F. Neumaier, Adrian Newman-Tancredi, Hugues Nury, Alexander Roberts, Bryan L. Roth, Anne Roumier, Gareth J. Sanger, Milt Teitler, Trevor Sharp, Carlos M. Villalón, Horst Vogel, Stephanie W. Watts & Daniel Hoyer. (2020) International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacological Reviews 73:1, pages 310-520.
Crossref
Crossref
Francesca Calabrese, Frank I. Tarazi, Giorgio Racagni & Marco A. Riva. (2019)
The role of dopamine D
3
receptors in the mechanism of action of cariprazine
. CNS Spectrums 25:3, pages 343-351.
Crossref
Crossref
Marlene Jacobson, Wayne Childers & Magid Abou‐Gharbia. 2019. Successful Drug Discovery. Successful Drug Discovery
83
130
.
Paul Cumming & Gerhard Gründer. 2019. Translational Medicine in CNS Drug Development. Translational Medicine in CNS Drug Development
159
172
.
Marianne O. Klein, Daniella S. Battagello, Ariel R. Cardoso, David N. Hauser, Jackson C. Bittencourt & Ricardo G. Correa. (2018) Dopamine: Functions, Signaling, and Association with Neurological Diseases. Cellular and Molecular Neurobiology 39:1, pages 31-59.
Crossref
Crossref
Jin-Hui WangJin-Hui Wang. 2019. Associative Memory Cells: Basic Units of Memory Trace. Associative Memory Cells: Basic Units of Memory Trace
257
275
.
Krzysztof Marciniec, Rafał Kurczab, Maria Książek, Ewa Bębenek, Elwira Chrobak, Grzegorz Satała, Andrzej J. Bojarski, Joachim Kusz & Paweł Zajdel. (2018) Structural determinants influencing halogen bonding: a case study on azinesulfonamide analogs of aripiprazole as 5-HT1A, 5-HT7, and D2 receptor ligands. Chemistry Central Journal 12:1.
Crossref
Crossref
Thiago C. Genaro-Mattos, Keri A. Tallman, Luke B. Allen, Allison Anderson, Karoly Mirnics, Zeljka Korade & Ned A. Porter. (2018) Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. Toxicology and Applied Pharmacology 349, pages 21-28.
Crossref
Crossref
Daniela Fanni, Clara Gerosa, Monica Rais, Alberto Ravarino, Peter Van Eyken, Vassilios Fanos & Gavino Faa. (2018) The role of neuropathological markers in the interpretation of neuropsychiatric disorders: Focus on fetal and perinatal programming. Neuroscience Letters 669, pages 75-82.
Crossref
Crossref
Se Joo Kim. (2018) Pharmacological Treatment Strategies for Acute Bipolar Depression. Journal of Korean Neuropsychiatric Association 57:4, pages 287.
Crossref
Crossref
Vanja Duric, Mounira Banasr, Tina Franklin, Ashley Lepack, Nika Adham, Béla Kiss, István Gyertyán & Ronald S. Duman. (2017) Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model. International Journal of Neuropsychopharmacology 20:10, pages 788-796.
Crossref
Crossref
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. KyneJr.Jr., Kevin K. -C. Liu, Sarah J. Fink & Christopher J. O’Donnell. (2017) Synthetic Approaches to the New Drugs Approved During 2015. Journal of Medicinal Chemistry 60:15, pages 6480-6515.
Crossref
Crossref
Xiao-Wen Chen, Yuan-Yuan Sun, Lei Fu & Jian-Qi Li. (2016) Synthesis and pharmacological characterization of novel N -( trans -4-(2-(4-(benzo[ d ]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics. European Journal of Medicinal Chemistry 123, pages 332-353.
Crossref
Crossref
Sidney H. KennedyRaymond W. LamRoger S. McIntyre, S. Valérie Tourjman, Venkat Bhat, Pierre Blier, Mehrul Hasnain, Fabrice Jollant, Anthony J. Levitt, Glenda M. MacQueen, Shane J. McInerney, Diane McIntosh, Roumen V. Milev, Daniel J. Müller, Sagar V. Parikh, Norma L. Pearson, Arun V. Ravindran & Rudolf Uher. (2016) Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. The Canadian Journal of Psychiatry 61:9, pages 540-560.
Crossref
Crossref
Anna Chang & Susan H. Fox. (2016) Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management. Drugs 76:11, pages 1093-1118.
Crossref
Crossref
G. Gründer. (2016) Bedeutung des Arzneimittelmarktneuordnungsgesetzes für die PsychopharmakotherapieSignificance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy. Der Nervenarzt 87:4, pages 356-366.
Crossref
Crossref
H. Javelot. (2016) Psychopharmacologie de l’anxiété et de la dépression : aspects historiques, traitements actuels et perspectives. Annales Pharmaceutiques Françaises 74:2, pages 93-118.
Crossref
Crossref
Michael Poyurovsky & Abraham Weizman. (2015) Treatment of Antipsychotic-Related Akathisia Revisited. Journal of Clinical Psychopharmacology 35:6, pages 711-714.
Crossref
Crossref
Andrea de Bartolomeis, Carmine Tomasetti & Felice Iasevoli. (2015) Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs 29:9, pages 773-799.
Crossref
Crossref
Isabella Pacchiarotti, Andrea Murru, Georgios D. Kotzalidis, C. Mar Bonnin, Lorenzo Mazzarini, Francesc Colom & Eduard Vieta. (2015) Hyperprolactinemia and medications for bipolar disorder: Systematic review of a neglected issue in clinical practice. European Neuropsychopharmacology 25:8, pages 1045-1059.
Crossref
Crossref
Thomas M. Keck, William S. John, Paul W. Czoty, Michael A. Nader & Amy Hauck Newman. (2015) Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis. Journal of Medicinal Chemistry 58:14, pages 5361-5380.
Crossref
Crossref
Walter Dunn & Stephen R. Marder. (2015) Novel Treatments of Psychosis. Current Behavioral Neuroscience Reports 2:2, pages 119-126.
Crossref
Crossref
Jean-Martin Beaulieu, Stefano Espinoza & Raul R Gainetdinov. (2015) Dopamine receptors - IUPHAR Review 13. British Journal of Pharmacology 172:1, pages 1-23.
Crossref
Crossref